Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Combined With Apatinib and Capecitabine for Advanced Biliary Tract Cancer
NCT04720131Phase 2Completed
- Sponsor
- Beijing Friendship Hospital
- Start
- Jan 2021
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in biliary tract cancer (BTC), sponsored by Beijing Friendship Hospital. Started Jan 2021; status: completed.
02
Drugs
camrelizumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04720131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04720131.